This retrospective study is to collect and analyze the data from medical records within the period that breast cancer patient is receiving NHI-covered CRF treatment. This study will evaluate the clinical use, fatigue improvement, and treatment satisfaction of breast cancer patients with CRF treatment.
This is a single arm, multicenter, and retrospective study. About 200 breast cancer patients' data from medical records are expected to collect and analyze in this retrospective study. The data collection from medical records of breast cancer patients who approved to use NHI to pay for CRF treatment drug will include the demographic information, disease characteristics and cancer treatment information, fatigue score by visual analog fatigue scale, fatigue clinical global impression, CRF pharmacological treatment record, hematological lab data, ECOG, cancer drug compliance record, overall clinical evaluation after CRF treatment by physicians and patient's expectation to continue CRF treatment etc. Data of three return visits (i.e. at the time of before CRF treatment, after 4 times of CRF treatment and CRF treatment completed) per patient will be collected from medical records to analysis within the period that patient is receiving NHI-covered CRF treatment.
Study Type
OBSERVATIONAL
Enrollment
261
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Keelung
Keelung, Taiwan
China Medical University Hospital
Taichung, Taiwan
Fatigue Improvement
Time frame: through study completion, an average of 4 months
The Level of Fatigue Clinical Global Impression-Improvement
Time frame: through study completion, an average of 4 months
Physician Satisfaction Degree of Overall Clinical Evaluation
Time frame: 1 time, average of 4 months after baseline (at the end of study)
Patient Expectation Rating of Continuous Cancer-Related Fatigue Treatment
Time frame: 1 time, average of 4 months after baseline (at the end of study)
ECOG Change
Time frame: through study completion, an average of 4 months
Weight Change
Time frame: through study completion, an average of 4 months
Hematological Lab Data Change
Time frame: through study completion, an average of 4 months
The Incidence of Cancer Treatent Delay
Time frame: through study completion, an average of 4 months
The Incidence of Cancer Treatent Dose Modification
Time frame: through study completion, an average of 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Taichung Veterans General Hospital
Taichung, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
Taipei Chang Gung Memorial Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan